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Abstract
Background: Budding is a complementary prognostic factor for colorectal cancer. In this study, we aimed to clarify
the role of tumor budding in rectal cancer patients after preoperative chemoradiotherapy.
Methods: A total of 124 patients with rectal cancer treated with neoadjuvant chemoradiotherapy and consecutive
surgery were included. Surgical specimens were evaluated for budding and routine clinicopathological features.
Budding was evaluated on hematoxylin and eosin (H&E)-stained slides and by cytokeratin immunohistochemical
(IHC) staining.
Results: A budding rate of 36.9% (n = 38) by H&E and 55.6% (n = 55) by IHC was observed. Budding was
significantly associated with a high ypT and ypN status, poor differentiation, and low degrees of tumor regression.
Moreover, budding was strongly predictive of a worse patient outcome, as measured by tumor recurrence or death.
In multivariate analyses, budding remained the only significant parameter for overall survival and was even superior
to the ypT and ypN status (budding in H&E: hazard ratio (HR) 2.72, 95% confidence interval (95% CI) 1.15–6.44, p =
0.023; budding in IHC: HR 5.19, 95% CI 1.62–16.61, p = 0.006).
Conclusion: Budding is a strong prognostic predictor of survival in rectal cancer patients after neoadjuvant therapy.
A standardized evaluation of tumor budding after neoadjuvant therapy may thus aid in risk stratification and guide
the clinical management of patients with rectal cancer. Immunostaining can help to enhance the diagnostic
accuracy and prognostic significance.
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Background
Locally advanced rectal cancers are treated with pre-
operative local radiation and simultaneous chemother-
apy. Since the implementation of this therapy, the risk
for local recurrence has notably decreased, and
sphincter-preserving surgery is more often performed [1,
2]. After such intensive therapy, the initial morphology
of the tumor is subject to considerable changes. Never-
theless, the evaluation of these histologically changed
cancers remains the same as for tumors without neoad-
juvant therapy. The tumor, node, metastasis (TNM) sta-
ging system, which is continuously updated, is widely
used to predict outcomes and aids in clinical decision
making in colorectal cancer. However, after preoperative
therapy, the prognostic impact of the classical TNM sys-
tem is subject to certain limitations, especially in tumors
with wide fibrotic areas, i.e., a major therapeutic re-
sponse [3]. Furthermore, the assessment of tumor re-
gression, the relation of residual cancer cells to fibrosis,
is an important feature of pathohistological evaluation
protocols of rectal cancer after neoadjuvant therapy.
Other morphological parameters have not yet been
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clarified as to whether they play a decisive role in the
prognostic prediction of treated rectal cancer. They
might constitute, however, a valuable addition to the
TNM system and regression grading of treated rectal
cancers.
An example of such a morphological parameter, the
role of which is not yet clear in tumors treated with neo-
adjuvant therapy, is tumor budding. In rectal cancers
without preoperative multimodality treatment, budding
is associated with lymphovascular invasion [4–6], meta-
static lymph nodes [4, 6–8], a higher TNM stage [6, 8],
and distant metastasis [6, 9]. In colorectal carcinoma,
budding is a strong adverse prognostic marker [4–9].
The aim of this retrospective study was to investigate
whether tumor budding is a prognostic factor for sur-
vival in patients with rectal cancer who received neoad-
juvant chemoradiotherapy. Special attention was paid to
tumor budding assessed with the method introduced by
Ueno et al. [10].
Methods
Patients
The study cohort included 124 consecutive patients with
a biopsy-proven diagnosis of rectal adenocarcinoma and
received radical surgery after neoadjuvant treatment be-
tween 2002 and 2011. All patients provided written con-
sent to further investigate their tissue samples as well as
the anonymous use of their clinical data. Patients under
the age of 18 were not included in the study. Investiga-
tions on archived tissue and anonymized data were ap-
proved by the institutional ethics board (№. EA1/370/
16). Primary clinical parameters and survival data were
obtained from electronic health records. Distant metas-
tasis had been excluded or detected at diagnosis and
during the follow-up by abdominal ultrasound and chest
radiography according to national guidelines. In cases of
suspicion or ambiguity, computed tomography (CT)
scans were performed [11]. Missing survival data at
follow-up were gathered by delivering a questionnaire to
the primary care physicians of the patients.
Neoadjuvant therapy and surgery
All 124 included patients received long-course neoadju-
vant therapy. Eighty patients were treated in strict com-
pliance with the standard regimen, defined by a
cumulated radiation dose of 50.4 Gy applied in 5 weekly
fractions of 1.8 Gy using 18MeV photons. These pa-
tients received a continuous infusion of 225 mg 5-FU
per day and square meter of body surface for the dur-
ation of radiotherapy. Most of the remaining 44 patients
received only slightly variant chemotherapy along with
hyperfractionated radiation. After an interval of 4–6
weeks, total mesorectal (TME) surgery was performed.
Pathological assessment
The quality of the total mesorectal excision was assessed
using the Quirke criteria. Quirke grade 1 (poor) corre-
sponds to irregular mesorectal fascia, with defects or in-
cisions up to 1 square cm to the muscularis propria,
irregular circumferential resection margin with small
amount of mesorectal fat and low anterior safety margin.
Quirke grade 2 (suboptimal) means that there is a mod-
erate amount of mesorectum with some irregularity;
moderate distal coning may be present. Quirke grade 3
(optimal) indicates that there is a good amount of
mesorectum, a smooth surface, a good safety distance at
the frontside and no defects in the mesorectum. Tissue
sections were prepared from paraffin-embedded samples,
mounted onto glass slides, stained with hematoxylin–
eosin according to standard procedures, and examined
with a Nikon ECLIPSE E200 microscope and a × 10 ocu-
lar lens. The pathological T and N stage (ypT and ypN,
respectively) were evaluated according to the 7th AJCC
TNM classification. The tumor regression grade of the
resected tumor was assessed using the original score
proposed by Dworak et al. [12]. Tumor regression was
described as follows: Grade 0: no regression; Grade 1:
dominant tumor mass with obvious fibrosis and/or vas-
culopathy; Grade 2: dominant fibrotic changes with few
tumor cells or groups (easy to find); Grade 3: very few
(difficult to find microscopically) tumor cells in fibrotic
tissue; and Grade 4: no tumor cells, only a fibrotic mass
(total regression or response). All formerly determined
histopathological features, such as regression grade or
pathological T and N stage, were retrospectively reevalu-
ated by one trained observer (I.T.) who was blinded to
patient outcomes and reviewed by a specialist gastro-
intestinal pathologist (S.E.).
Tumor budding
Tumor budding was defined as a single tumor cell or a
cluster of up to four tumor cells in the invasive front of
the tumor or within the tumor. For quantifications, the
sections were first scanned at a low power, and an area
with maximal budding was identified. Then, tumor buds
were counted in one field measuring 0.785 mm2 using a
20x objective lens. A field with five or more buds was
viewed as budding positive (BD-1), while a field with
four or fewer buds was viewed as budding negative (BD-
0) [10].
Immunohistochemical staining
In addition, to better understand tumor budding after
neoadjuvant treatment and to highlight buds in detail,
we also performed immunohistochemical (IHC) staining.
There were 99 corresponding unstained tissue slides
available for immunohistochemistry with a pan-
cytokeratin antibody AE1/AE3. Staining was performed
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according to standard protocols provided by the auto-
mated Ventana BenchMark XT immunostainer (Ventana
Medical Systems, Inc., Tucson, AZ, USA). Briefly, the
tissue sections were deparaffinized and rehydrated and
subjected to heat-induced epitope retrieval and endogen-
ous peroxidase blocking with H2O2. Subsequently, the
slides were incubated with a primary pan-cytokeratin
antibody (clone AE1/AE3, dilution 1:500, DAKO) for 60
min and then with a horseradish peroxidase (HRP)-con-
jugated secondary antibody (DISCOVERY Universal Sec-
ondary Antibody (RUO)) for 32 min. This was followed
by applying the chromogen 3,3′-diaminobenzidine-tetra-
hydrochloride (DAB) for 8 min and counterstaining with
hematoxylin and bluing reagent (Ventana Medical Sys-
tems, Inc.) for 12 min. Budding was evaluated on IHC-
stained slides with the same method and cut-off as de-
scribed above for H&E-stained slides.
Statistical analysis
We compared the BD-0 and BD-1 groups using the chi-
squared test or Fisher’s exact test, as appropriate. Compar-
isons of the means of metrical variables, such as age, BMI,
tumor size, circumferential resection margin between the
BD-0 and BD-1 groups were performed using a t-test for
independent samples. Univariate and multivariate Cox
proportional hazards regression models were used to esti-
mate hazard ratios (HRs) with 95% confidence intervals
(95% CIs). For categorical variables, the lowest value
served as the reference category. The categorical variables
used in the univariate analyses were gender (male versus
female), American Society of Anesthesiologists (ASA)
classification (2 and 3 versus 1), cM stage, type of resec-
tion (Abdominoperineal resection versus lower anterior
resection), adjuvant therapy, Quirke Grade (poor versus
moderate and good), higher ypT stage (ypT3–4 versus
ypT0–2), positive ypN stage (ypN+ versus ypN0), higher
histological and regressive grading, vascular and perineu-
ral invasion (V1, L1, Pn1), quality of resection (R+ versus
R0) and positive budding. The continuous variables used
in univariate analyses were age at surgery, body mass
index (BMI), tumor size and circumferential resection
margin (CRM). Covariates and factors included in the
multivariate regression analysis were budding and ypT
and ypN stage. Dichotomization of ypT and ypN stages
was used to avoid overfitting of the model. The primary
endpoints of the study were the hazard ratios for disease-
free survival (DFS) and overall survival (OS). Overall sur-
vival (OS) was defined as the time from the date of surgery
to the date of death from any cause. Disease-free survival
(DFS) was defined as the time from the date of surgery to
the date of pelvic recurrence and/or distant disease or
death from any cause. Kaplan-Meier survival curves show
the influence of tumor budding on survival. The different
budding categories (BD-0 and BD-1) in the plotted DFS
and OS curves were compared using the log-rank test.
With the kappa value, we evaluated the consistency of
H&E-stained slides with IHC-stained slides. All tests were
two-sided, and the level of significance was set at α = 0.05.
We performed all statistical analyses using SPSS Statistics
24.0 Software (SPSS, Inc., Chicago, IL).
Results
The initial study cohort included 124 patients, 87 men
(70.2%) and 37 women (29.8%), with a mean age of 64.7
years (range 34–87 years). The TNM classification before
neoadjuvant treatment was composed as follows: cT2 in
12 patients (9.7%), cT3 in 92 patients (74.2%) and cT4 in
20 patients (16.1%); cN0 in 14 patients (11.3%) and cN+
in 110 patients (88.7%); cM0 in 111 (89.5%) and cM1 in
13 (10.5%) patients. Lower anterior resection (LAR) was
performed on 92 patients (74.2%), abdominal perineal
resection on 32 patients (25.8%). The average number of
harvested lymph nodes was 18 (range 5–67). The quality
of mesorectum specimens was poor in 5 (4.0%), subopti-
mal in 19 (15.3%) and optimal in 86 (69.4%) resected
rectal cancers. In 14 (11.3%) it was not described. A
complete resection with R0 status was achieved in 118
patients (95.2%). Adjuvant chemotherapy was received
in 71 (57.3%) cases, while in 32 (25.8%) cases the tumor
board decided against adjuvant therapy. For 21 (16.9%)
patients information on adjuvant therapy was not
available.
There were seven local recurrences (5.6%) and eight-
een distant recurrences (14.5%) in the follow-up period.
Thirty-two patients (25.8%) died during the follow-up
period. The mean time for recurrence was 28.4 months
(standard deviation 24.6 months, maximum 94months).
The mean follow-up time was 54.7 months (standard de-
viation 35.5 months, maximum 134months).
Evaluation of tumor budding by H&E and IHC
In the following tumor budding analyses, we examined
only specimens with residual tumor. Twenty-one speci-
mens with pathological complete response (pCR) were
excluded from further statistical analyses. Without 21
pCR cases, there were 103 cases available for analysis of
H&E-stained tissue sections, and 99 cases for analysis of
IHC-stained tissue sections (Fig. 1). The examination of
H&E-stained sections showed 38 (36.9%) budding-
positive cases and 65 (63.1%) budding-negative cases.
On IHC-stained sections, 44 cases (44.4%) were budding
negative, and 55 cases (55.6%) were budding positive;
thus, there was a higher percentage compared to H&E-
stained slides. Figure 2 illustrates an example of a
budding-negative case and a budding-positive case from
both staining methods.
To evaluate the consistency of budding evaluated on
H&E- or IHC-stained sections, we used fourfold tables
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(Table 1). After immunohistochemical staining, there
were more budding-positive cases. The assessment of
tumor budding on H&E and IHC reached good agree-
ment, with a kappa value of 0.609. The evaluation of
budding on H&E-stained slides compared well with the
evaluation of budding on IHC-stained slides.
Tumor budding is associated with adverse
clinicopathological features
As analyzed by H&E staining, budding was found more
frequently in specimens of elderly patients (p = 0.032), in
patients with a lower BMI (p = 0.042) and in patients
with a higher ASA score (p = 0.022). Patients in whom
Fig. 1 Flow chart of histological analysis for the study cohort
Fig. 2 Comparison of tumor budding in neoadjuvant treated rectal cancers in both hematoxylin-eosin and in immunohistochemical staining.
Tumor budding was defined as a single tumor cell or a cluster up to four tumor cells at the invasive front or within the tumor as well. Tumor
buds were counted in one field measuring 0.785mm2 using a 20x objective lens. A field with 4 buds or fewer was viewed as budding negative
(a-d), a field with 5 or more buds was viewed as budding positive (e-h). Boxed areas are shown in a higher magnification on the right side of the
corresponding picture. (Original magnification and staining method: (a) × 40, H&E; (b) × 200, H&E; (c) × 40, AE1/AE3; (d) × 200, AE1/AE3; (e) × 40,
H&E; (f) × 200, H&E; (g) × 40, AE1/AE3; (h) × 200, AE1/AE3;)
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lower anterior resection was performed had significantly
less budding (p = 0.004). Budding was also significantly
associated with a higher T stage, both before and after
neoadjuvant therapy (for cT stage p = 0.005 and for ypT
stage p = 0.001), metastatic lymph nodes (for ypN stage
p = 0.006), a poorer level of histological differentiation
(p = 0.021), a lower response according to Dworak’s
tumor regression grading scale (p = 0.001), venous or
perineural invasion (p = 0.030 and p = 0.001), and a
worse outcome in subsequent observations, such as can-
cer recurrence (p = 0.002) or death (p = 0.006). Tumors
with a smaller circumferential resection margin and a
poor quality of mesorectal excision (Quirke Grade poor)
also had significantly more budding (p = 0.010 and p =
0.004, respectively). There were no significant associa-
tions between budding and sex (p = 0.501), the mean
macroscopically evaluated tumor size (p = 0.192), syn-
chronous metastasis at the time of surgery (p = 0.066),
or metastatic lymph nodes before neoadjuvant treatment
(p = 0.742). The parameters mentioned above can be
found in Tables 2 and 3. The clinicopathological features
of budding in IHC-stained specimens are listed in Tables
2 and 3.
Many factors influence the survival of rectal cancer
patients
In univariate analysis, factors such as a higher ypT stage,
metastatic lymph nodes, vascular and perineural inva-
sion, synchronous metastasis at the time of surgery,
poorly differentiated and macroscopically larger tumors
and positive budding (evaluated in both staining
methods) had a significantly negative impact on disease-
free survival. A higher BMI, larger circumferential resec-
tion margins on tumor specimens and more regression
had a significantly positive impact on disease-free sur-
vival. All these variables with the corresponding hazard
ratios can be found in Table 4.
In univariate analyses on overall survival, age and syn-
chronous metastasis at the time of surgery, a poorer
quality mesorectal excision, a higher ypT stage, perineu-
ral invasion, poorly differentiated tumors and positive
budding, independent of the staining method, had a sig-
nificantly negative impact on overall survival. Lymph
node stage had no significant influence on overall sur-
vival. Similar to disease-free survival, prolonged overall
survival was associated with tumor specimens with lar-
ger circumferential resection margins and patients with
more regression and in patients with a higher BMI. All
these variables with the corresponding hazard ratios can
be found in Table 5.
Budding is an independent prognostic factor for disease-
free survival and overall survival in multivariate cox
proportional hazards regression models
In the multivariate analysis, budding scored on H&E-
stained sections (HR 2.34, 95% CI 1.14–4.79; p = 0.020)
and ypT stage (HR 2.85, 95% CI 1.16–7.02; p = 0.023)
were both independent predictors of disease-free survival
(Table 6). In the multivariate analysis, when budding
was evaluated on IHC-stained sections, positive budding
(HR 4.59, 95% CI 1.79–11.72; p = 0.001) remained the
only independent prognostic factor (Table 7). In the
multivariate regression analysis of overall survival, only
tumor budding remained a significant parameter (H&E:
HR 2.72, 95% CI 1.15–6.44, p = 0.023; IHC: HR 5.19,
95% CI 1.62–16.61, p = 0.006) and was even superior to
the ypT and ypN status (Tables 8 and 9).
The prognostic impact of budding is confirmed by
Kaplan–Meier survival analysis
With the H&E staining method, for patients with
budding-positive tumors, the five-year disease-free sur-
vival rate was 39.0%, and for those without budding, the
rate was 75.0%. With the IHC staining method, for pa-
tients with budding-positive tumors, the five-year
disease-free survival rate was 44.0%, and for those with-
out budding, the rate was 87.0%. Furthermore, for pa-
tients with positive budding evaluated on H&E-stained
sections, the five-year overall survival rate was 53.0%,
and for those without budding, the rate was 84.0%. On
IHC-stained sections, the five-year overall survival rate
was 59.0% for patients with budding-positive tumors and
92.0% for those without budding. Independent of the
staining method, patients with positive budding had sig-
nificantly poorer DFS and OS compared to those with-
out budding (Fig. 3).
Discussion
In the present study, we investigated whether tumor
budding is a prognostic factor in patients with rectal
adenocarcinoma treated with neoadjuvant therapy. Our
results showed a strong connection between posttreat-
ment budding and a more aggressive tumor biology, i.e.,
correlation with adverse clinicopathological features,
such as deeper tumor infiltration or a higher frequency
of lymph node metastases. Irrespective of the staining
method used, patients with tumor budding had a signifi-
cantly worse prognosis for disease-free survival and
overall survival. These aspects have already been
Table 1 Comparison of cases where budding was evaluated on
H&E with cases budding evaluated on IHC
Budding on IHC
negative positive n
Budding on H&E negative 44 20 64
positive 0 35 35
n 44 55 99
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Table 2 Tumor budding and associations with clinical features
Budding on H&E Budding on IHC
negative positive P negative positive P
All patients, n (%) 65 (63.1) 38 (36.9) 44 (44.4) 55 (55.6)
Age
Mean, years (SD) 62.5 (9.2) 67.1 (10.8) 0.032 61.8 (9.8) 65.7 (9.8) 0.055
Sex, n (%)
Male 48 (65.8) 25 (34.2) 0.501 34 (47.9) 37 (52.1) 0.370
Female 17 (56.7) 13 (43.3) 10 (35.7) 18 (64.3)
BMI
Mean, kg/m2 (SD) 25.8 (3.9) 23.6 (5.7) 0.042 25.6 (3.2) 24.6 (5.6) 0.252
ASA classification, n (%)
1 12 (85.7) 2 (14.3) 0.022 9 (64.3) 5 (35.7) 0.096
2 47 (64.4) 26 (35.6) 31 (44.9) 38 (55.1)
3 6 (37.5) 10 (62.5) 4 (25.0) 12 (75.0)
cT stage, n (%)
T0–1 – – – – 0.005 – – – – 0.011
T2 5 (55.6) 4 (44.4) 2 (22.2) 7 (77.8)
T3 54 (72.0) 21 (28.0) 39 (53.4) 34 (46.6)
T4 6 (31.6) 13 (68.4) 3 (17.6) 14 (82.4)
cN stage, n (%)
N0 7 (70.0) 3 (30.0) 0.742 7 (70.0) 3 (30.0) 0.104
N+ 58 (62.4) 35 (37.6) 37 (41.6) 52 (58.4)
cM stage, n (%)
M0 60 (66.7) 30 (33.3) 0.066 42 (47.2) 47 (52.8) 0.178
M1 5 (38.5) 8 (61.5) 2 (20.0) 8 (80.0)
Type of resection, n (%)
LAR 53 (71.6) 21 (28.4) 0.004 39 (53.4) 34 (46.6) 0.003
APR 12 (41.4) 17 (58.6) 5 (19.2) 21 (80.8)
Adjuvant therapy, n (%)
Yes 42 (66.7) 21 (33.3) 0.218 27 (45.0) 33 (55.0) 0.741
No 12 (52.2) 11 (47.8) 9 (40.9) 13 (59.1)
Not described 11 6 8 9
Relapse in the follow-up period, n (%)
No 57 (71.3) 23 (28.7) 0.002 41 (53.9) 35 (46.1) 0.001
Yes 8 (34.8) 15 (65.2) 3 (13.0) 20 (87.0)
Type of relapse, n (%)
Local recurrence 2 (50.0) 2 (50.0) 0.015 1 (25.0) 3 (75.0) 0.003
Liver 2 (28.6) 5 (71.4) 0 (0) 7 (100)
Lung 3 (33.3) 6 (66.7) 1 (11.1) 8 (88.9)
Cerebral 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7)
Survival status in follow-up, n (%)
Alive 54 (71.1) 22 (28.9) 0.006 40 (53.3) 35 (46.7) 0.002
Dead 11 (40.7) 16 (59.3) 4 (16.7) 20 (83.3)
Abbreviations: pCR pathological complete response, P = P-value, SD standard deviation, BMI body mass index, ASA American Society of Anesthesiologists, LAR low
anterior resection, APR abdominoperineal excision. Significant p-values are represented in bold type
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Table 3 Tumor budding and associations with pathological features
Budding on H&E Budding on IHC
negative positive P negative positive P
All patients, n (%) 65 (63.1) 38 (36.9) 44 (44.4) 55 (55.6)
Tumor size
Mean, cm (SD) 2.9 (1.4) 3.4 (2.2) 0.192 2.7 (1.4) 3.3 (2.0) 0.064
CRM
Mean, mm (SD) 18.4 (18.3) 9.4 (15.8) 0.010 19.1 (15.6) 12.4 (19.3) 0.061
Quirke Grade, n (%)
Poor 0 (0) 5 (100) 0.004 0 (0) 4 (100) 0.218
Suboptimal 13 (81.3) 3 (18.8) 8 (50.0) 8 (50.0)
Optimal 49 (69.0) 22 (31.0) 34 (48.6) 36 (51.4)
Not described 3 8 2 7
ypT stage, n (%)
T0–1 10 (100) 0 (0) 0.001 9 (90.0) 1 (10.0) 0.001
T2 26 (81.3) 6 (18.8) 19 (61.3) 12 (38.7)
T3 25 (49.0) 26 (51.0) 15 (30.6) 34 (69.4)
T4 4 (40.0) 6 (60.0) 1 (11.1) 8 (88.9)
ypN stage, n (%)
N0 40 (76.9) 12 (23.1) 0.006 29 (58.0) 21 (42.0) 0.021
N1 20 (54.1) 17 (45.9) 12 (32.4) 25 (67.6)
N2 5 (35.7) 9 (64.3) 3 (25.0) 9 (75.0)
Grading, n (%)
G1 2 (66.7) 1 (33.3) 0.021 2 (66.7) 1 (33.3) 0.290
G2 47 (67.1) 23 (32.9) 31 (44.9) 38 (55.1)
G3 16 (64.0) 9 (36.0) 11 (47.8) 12 (52.2)
G4 0 (0) 5 (100) 0 (0) 4 (100)
Dworak’s regression, n (%)
Grade 1 2 (20.0) 8 (80.0) 0.001 1 (10.0) 9 (90.0) 0.001
Grade 2 47 (62.7) 28 (37.3) 29 (40.8) 42 (59.2)
Grade 3 16 (88.9) 2 (11.1) 14 (77.8) 4 (22.2)
Venous invasion, n (%)
V0 58 (68.2) 27 (31.8) 0.030 38 (46.3) 44 (53.7) 0.404
V1 7 (38.9) 11 (61.1) 6 (35.3) 11 (64.7)
Lymphatic invasion, n (%)
L0 61 (66.3) 31 (33.7) 0.055 44 (50.0) 44 (50.0) 0.001
L1 4 (36.4) 4 (63.6) 0 (0) 11 (100)
Perineural invasion, n (%)
Pn0 62 (71.3) 25 (28.7) 0.001 43 (51.2) 41 (48.8) 0.001
Pn1 3 (18.8) 13 (81.3) 1 (6.7) 14 (93.3)
Resection margin, n (%)
R0 64 (66.0) 33 (34.0) 0.021 43 (45.7) 51 (54.3) 0.792
R1 1 (20.0) 4 (80.0) 1 (25.0) 3 (75.0)
R2 0 (0) 1 (100) 0 (0) 1 (100)
Abbreviations: pCR pathological complete response, P P-value, SD standard deviation, CRM circumferential resection margin. Significant p-values are represented in
bold type
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described in patients with chemotherapy-naïve colorectal
cancer [4–9] and included as a recommendation in
major national guidelines for the assessment of early in-
vasive cancer [11, 13, 14].
Budding has been described as a prognostic feature
after chemoradiotherapy in rectal cancer patients in sev-
eral publications with the general limitation of a retro-
spective study design. In previous studies, budding was
reported in 10.1–63.2% of cases due to different method-
ologies used for evaluation [3, 15–20]. Budding has been
shown to be a negative prognostic factor for survival in
different kinds of study designs and for a broad range of
cut-offs. However, most of the previous studies could
demonstrate effects on survival only in univariate ana-
lysis or limited to disease free survival [15–19]. Including
patients with complete response in the analysis appeared
to attenuate the prognostic impact of tumor budding. In
our opinion, it is self-evident that budding cannot be
evaluated in patients with a complete response. There-
fore, in our study, we focused on cases with poor re-
sponse in order to stratify the outcome of patients with
residual tumor burden. By this approach, we were able
to demonstrate a strong impact on disease free survival
and overall survival in univariate and multivariate
analysis.
Of the most recent studies, Jäger et al. [3] can be com-
pared to our own study. As in our study, they evaluated
budding not only at the invasive front but also through-
out the tumor. The high budding rate of 63.2% com-
pared to our results can be explained by the low cut-off
of two buds in one microscopic field, whereas in our
study a cutoff of 5 buds was used according to standard
criteria of Ueno et al. [10]. As in our study, budding
remained a significant parameter in multivariate analysis
Table 4 Univariate cox regression analysis of DFS
Disease-free survival
Parameter HR 95% CI P
Age 1.03 [0.99; 1.06] 0.124
Male vs. female 0.63 [0.32; 1.24] 0.177
BMI 0.91 [0.85; 0.98] 0.009
ASA 2 and 3 2.04 [0.62; 6.66] 0.238
cM1 7.58 [3.42; 16.79] < 0.001
Type of resection: APR vs. LAR 1.83 [0.92; 3.62] 0.083
Adjuvant therapy recieved 0.99 [0.44; 2.21] 0.979
Tumor size 1.02 [1.00; 1.04] 0.048
CRM 0.93 [0.88; 0.97] 0.002
Poor Quirke Grade 1.78 [0.99; 3.18] 0.053
Higher ypT stage [ypT3–4] 4.20 [1.83; 9.66] 0.001
ypN+ 2.34 [1.16; 4.68] 0.017
Histological Grading 1.97 [1.20; 3.25] 0.008
Tumor regression Grading 0.35 [0.16; 0.75] 0.007
Budding positive H&E 3.54 [1.82; 6.89] < 0.001
Budding positive IHC 6.23 [2.57; 15.31] < 0.001
V1 2.41 [1.16; 5.03] 0.019
L1 2.75 [1.20; 6.32] 0.017
Pn1 5.49 [2.65; 11.37] 0.001
R+ 1.51 [0.36; 6.35] 0.573
Abbreviations: DFS disease-free survival, HR hazard ratio, 95% CI 95%
confidence interval, P P-value, BMI body mass index, ASA American Society of
Anesthesiologists, APR abdominoperineal excision, LAR low anterior resection,
CRM circumferential resection margin, Pn1 perineural invasion; R+ = invaded
margin. Significant p-values and corresponding hazard ratios are represented
in bold type
Table 5 Univariate cox regression analysis of OS
Overall survival
Parameter HR 95% CI P
Age 1.06 [1.01; 1.10] 0.010
Male vs. female 0.54 [0.25; 1.16] 0.114
BMI 0.97 [0.84; 0;97] 0.006
ASA 2 and 3 2.21 [0.52; 9.37] 0.282
cM1 6.53 [2.74; 15.54] 0.001
Type of resection: APR vs. LAR 1.77 [0.80; 3.89] 0.156
Adjuvant therapy 1.23 [0.45; 3.37] 0.681
Tumor size 1.01 [0.98; 1.03] 0.554
CRM 0.95 [0.90; 0.99] 0.043
Poor Quirke Grade 2.72 [1.47; 2.47] 0.001
Higher ypT stage [ypT3–4] 3.01 [1.20; 7.55] 0.019
ypN+ 1.64 [0.74; 3.63] 0.220
Histological Grading 2.24 [1.26; 3.97] 0.006
Tumor regression Grading 0.19 [0.07; 0.51] 0.001
Budding positive H&E 3.43 [1.57; 7.52] 0.002
Budding positive IHC 5.76 [1.95; 17.01] 0.002
V1 1.60 [0.64; 3.99] 0.316
L1 1.90 [0.70; 5.18] 0.209
Pn1 3.76 [1.60; 8.85] 0.002
R+ 1.01 [0.14; 7.49] 0.993
Abbreviations: OS overall survival, HR hazard ratio, 95% CI 95% confidence
interval, P P-value, BMI body mass index, ASA American Society of
Anesthesiologists, APR abdominoperineal excision, LAR low anterior resection,
CRM circumferential resection margin, Pn1 perineural invasion, R+ = invaded
margin. Significant p-values and corresponding hazard ratios are represented
in bold type
Table 6 Multivariate cox regression analysis of DFS: Budding
evaluated on H&E
Disease-free survival
Parameter HR 95% CI P
Positive Budding H&E 2.34 [1.14; 4.79] 0.020
Higher ypT stage [ypT3–4] 2.85 [1.16; 7.02] 0.023
ypN+ 1.34 [0.63; 2.83] 0.449
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for disease free survival. However they failed to demon-
strate this for overall survival, presumably, because pa-
tients with complete response were included in the
statistical analysis.
Only one previous study claimed that a single cell pat-
tern of growth in the invasive front was a prognostic fac-
tor for prolonged cancer-specific survival [21]. They
interpreted the single-cell growth pattern as an indicator
of tumor cell regression. However, they did not evaluate
budding as a standardized parameter but rather as a
semiquantitative score of the tumor growth pattern. Fur-
thermore, patients with a complete pathological re-
sponse were included in the survival analysis,
undermining the impact of budding as a parameter for
the stratification of patients with a poor response.
In our study, immunohistochemical staining showed
that budding had a considerable prognostic influence
and was even superior to that of conventional parame-
ters such as ypT and ypN stage, which have been used
in routine so far. Therefore, the assumption arises that
the assessment of posttreatment budding may improve
the commonly used TNM classification for stratifying
rectal cancer patients treated with neoadjuvant therapy
and for predicting prognosis.
However, there is still a general lack of a unified defin-
ition of tumor budding. At the International Tumor
Budding Consensus Conference (ITBCC) in 2016, a con-
sensus for a standardized definition of budding and for
an evaluation method was reached, but only for colorec-
tal cancers without neoadjuvant chemoradiotherapy so
far [22]. Tumor budding was defined as a single cell or a
cluster of up to four tumor cells assessed in one hotspot
measuring 0.785 mm2 at the invasive front. Furthermore,
a three-tier system was recommended with a whole bud-
ding count to allow adequate risk stratification. The
documentation of tumor budding after neoadjuvant
therapy has not yet been suggested for daily diagnostic
practice because of data gaps in its prognostic value in
treated rectal cancers as well as a lack of a standardized
evaluation method for these cancers.
The initial morphology of the tumor is often modified
after chemoradiation, with phenomena such as heavy fi-
brosis, breaking up of the glandular tumor structures
and necrotic areas. Due to these factors, the assessment
of budding proposed by the ITBCC becomes challen-
ging. It should also be mentioned that after neoadjuvant
therapy, tumor borders may appear fragmented, so the
tumors occasionally form several invasive fronts in the
context of fibrosis and inflammation. Owing to these
histological changes, we assessed tumor budding not
only at the utmost invasive front (such as in cancers
without chemoradiation) but also in-between invasive
foci. Lugli et al. [23] and Rieger et al. [24] showed that
intratumoral budding in chemotherapy-naïve patients
with colorectal cancer is generally associated with peri-
tumoral budding. They found that as long as the obser-
ver investigates the densest region with budding, it does
not matter whether buds are detected at the invasive
front or within the tumor. Our method used to assess
budding without being limited to the invasive front in
neoadjuvant-treated cancers was fundamentally based on
those findings. With our method, we were able to ad-
dress the abovementioned problems occurring after pre-
operative therapy while keeping the method relatively
simple and potentially reproducible for other observers.
For our budding analyses, we used the one hotspot
method, as recommended by the ITBCC and originally
proposed by Ueno et al. [10]. It is a fast and simple way
to subdivide patients into two different categories that
are prognostically highly relevant. Even in patients with
little residual tumor after preoperative therapy, the
method was able to find high-risk patients. Although the
cut-off was set to merely 5 buds per hotspot, as pro-
posed for the stratification of pT1 carcinomas in polyps
[10], it was possible to apply the same cut-off for locally
advanced cancers, with a resulting high impact of both
disease-free survival and overall survival.
In addition to H&E staining, we used IHC staining to
make buds more readily visible. Kai et al. [25] were able
Table 7 Multivariate cox regression analysis of DFS: Budding
evaluated on IHC
Disease-free survival
Parameter HR 95% CI P
Positive Budding IHC 4.59 [1.79; 11.72] 0.001
Higher ypT stage [ypT3–4] 2.16 [0.87; 5.34] 0.095
ypN+ 1.29 [0.60; 2.77] 0.516
Table 8 Multivariate cox regression analysis of OS: Budding
evaluated on H&E
Overall survival
Parameter HR 95% CI P
Positive Budding H&E 2.72 [1.15; 6.44] 0.023
Higher ypT stage [ypT3–4] 2.17 [0.78; 6.06] 0.140
ypN+ 1.12 [0.46; 2.71] 0.803
Table 9 Multivariate cox regression analysis of OS: Budding
evaluated on IHC
Overall survival
Parameter HR 95% CI P
Positive Budding IHC 5.19 [1.62; 16.61] 0.006
Higher ypT stage [ypT3–4] 1.50 [0.53; 4.26] 0.443
ypN+ 1.18 [0.47; 2.92] 0.727
Abbreviations: DFS disease-free survival, OS overall survival, HR hazard ratio,
95% CI 95% confidence interval, P P-value. Significant p-values and
corresponding hazard ratios are represented in bold type
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to show that IHC can reduce interobserver variability in
the evaluation of budding between unskilled observers.
This would make IHC suitable for training pathologists
who are inexperienced in this field. As described in pre-
vious studies for colorectal cancers without prior
chemotherapy, cytokeratin staining detected more
budding-positive cases [26]. In our study, we detected
more budding-positive cases by the means of IHC stain-
ing as well, and this method improved the prognostic
value of tumor budding assessment. IHC helped to strat-
ify patients into even more meaningful risk groups than
H&E staining. When analyzed with IHC staining, fewer
budding-negative cases were found, and these had a bet-
ter prognosis than budding-negative cases found by
H&E (five-year disease-free survival rate: 87% vs 75%;
and five-year overall survival rate: 92% vs 84%). The
employed cut-off may therefore identify patients with a
favorable prognosis who might be able to refrain from
adjuvant therapy. If the cut-off for budding on IHC was
higher, high-risk patients would more likely come to
light. In these patients, more intensive aftercare might
be recommended. The ideal cut-off for the evaluation of
budding in IHC-stained sections still needs to be investi-
gated. In tumors without neoadjuvant therapy, the
ITBCC recommends the use of IHC in difficult cases
(such as for distinguishing buds from peritumoral in-
flammation reaction), but the final evaluation should still
be performed on H&E-stained slides [22]. In the case of
pretreated tumors, the role of IHC and H&E staining









BD-0 65 53 42 25 11
BD-1 38 18 11 6 2
BD-0 44 40 34 22 9
BD-1 55 30 18 9 4
BD-0 65 56 46 27 12
BD-1 38 23 15 8 3
BD-0 44 41 35 23 10
BD-1 55 37 25 12 5
p<0.001 p<0.001
p=0.001 p<0.001
Fig. 3 Kaplan-Meier curves for disease-free survival (DFS) and overall survival (OS). Independently of the staining method, DFS and OS were
significant poorer on budding positive cases (BD-1). a DFS and budding evaluated on H&E (Log-rank test p < 0.001). b DFS and budding
evaluated on IHC (Log-rank test p < 0.001). c OS and budding evaluated on H&E (Log-rank test p = 0.001). d OS and budding evaluated on IHC
(Log-rank test p < 0.001)
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tumor inflammation occurs in such cases, IHC might
play a more central role in the evaluation of these tu-
mors. So far, only two previous studies regarding IHC
staining in posttreatment budding exist [17, 18]. Con-
cerning this issue, more investigations should be
performed.
The main limitation of this work is its retrospective
nature. It also needs to be determined whether the num-
ber and composition of included patients may vary
among patients with different ethnic backgrounds. In
addition, the recorded number of events during the
follow-up could be a limitation as well, especially in the
interpretation of the Cox regression models due to the
possible lack of outcome data. Nevertheless, current data
on the prognosis of tumor budding in rectal cancers
treated with neoadjuvant therapy are unsatisfactory.
It is remarkable that lymph node status did not have a
significant effect on outcome in our multivariate survival
analysis. In fact, previous studies of neoadjuvant therapy
in rectal cancer found strong associations of lymph node
status with survival [27, 28]. However, in these studies,
patients with complete pathological response were in-
cluded in the analysis, who were here excluded due to
being non-informative for tumor budding. We speculate
that the specific case selection in our study may be the
cause of such discrepancies.
Conclusion
In conclusion, our study provides further information to
understand and evaluate budding in rectal carcinomas
treated with neoadjuvant therapy while analyzing bud-
ding on H&E- and immunostained specimens. Immuno-
histochemical staining can substantially enhance the
diagnostic accuracy and prognostic impact. Tumor bud-
ding should be taken more seriously into account in
daily diagnostic practice, since it represents an additional
and independent prognostic factor for therapeutic deci-
sion making, even in rectal cancer patients after pre-
operative therapy. The method of Ueno is well suited for
this purpose because of its fast and simple method of
evaluating budding-positive cases. However, more know-
ledge about budding and a consensus about the best
method used to assess buds after perioperative therapy
are strongly needed to standardize the process and to
speed up its application in pathological protocols for
treated rectal cancers.
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